The second factor contributing to the poor performance of microbially-delivered beta-glucuronidase appears to be related to localization of bacteria in necrotic areas of the tumor, which may hinder contact of systemically administered drugs and bacteria. The gene discussed is GUSB; the disease is neoplasm.